Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization

@inproceedings{Schueler2019InductionOA,
  title={Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization},
  author={Julia Schueler and Cordula Tschuch and Kerstin Klingner and Daniel Bug and Anne-Lise Peille and Leanne de Koning and Eva Oswald and Hagen Klett and Wolfgang Sommergruber},
  booktitle={Cells},
  year={2019}
}
In up to 30% of non-small cell lung cancer (NSCLC) patients, the oncogenic driver of tumor growth is a constitutively activated epidermal growth factor receptor (EGFR). Although these patients gain great benefit from treatment with EGFR tyrosine kinase inhibitors, the development of resistance is inevitable. To model the emergence of drug resistance, an EGFR-driven, patient-derived xenograft (PDX) NSCLC model was treated continuously with Gefitinib in vivo. Over a period of more than three… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 68 REFERENCES